Raffi F - Search Results

1

On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.

Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E, Pasquet A, Raffi F, Pintado C, Chidiac C, Chas J, Charbonneau P, Delaugerre C, Suzan-Monti M, Loze B, Fonsart J, Peytavin G, Cheret A, Timsit J, Girard G, Lorente N, Préau M, Rooney JF, Wainberg MA, Thompson D, Rozenbaum W, Doré V, Marchand L, Simon MC, Etien N, Aboulker JP, Meyer L, Delfraissy JF; ANRS IPERGAY Study Group. Molina JM, et al. Among authors: raffi f. N Engl J Med. 2015 Dec 3;373(23):2237-46. doi: 10.1056/NEJMoa1506273. Epub 2015 Dec 1. N Engl J Med. 2015. PMID: 26624850 Free article. Clinical Trial.

2

Lower survival in AIDS patients receiving dapsone compared with aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia. Study Group.

Salmon-Ceron D, Fontbonne A, Saba J, May T, Raffi F, Chidiac C, Patey O, Aboulker JP, Schwartz D, Vildé JL. Salmon-Ceron D, et al. Among authors: raffi f. J Infect Dis. 1995 Sep;172(3):656-64. doi: 10.1093/infdis/172.3.656. J Infect Dis. 1995. PMID: 7658056 Clinical Trial.

3

Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients.

Chêne G, Angelini E, Cotte L, Lang JM, Morlat P, Rancinan C, May T, Journot V, Raffi F, Jarrousse B, Grappin M, Lepeu G, Molina JM. Chêne G, et al. Among authors: raffi f. Clin Infect Dis. 2002 Mar 1;34(5):649-57. doi: 10.1086/338811. Epub 2002 Jan 24. Clin Infect Dis. 2002. PMID: 11810598 Clinical Trial.

4

Final analysis of the Trilège induction-maintenance trial: results at 18 months.

Flandre P, Raffi F, Descamps D, Calvez V, Peytavin G, Meiffredy V, Harel M, Hazebrouck S, Pialoux G, Aboulker JP, Brun Vezinet F. Flandre P, et al. Among authors: raffi f. AIDS. 2002 Mar 8;16(4):561-8. doi: 10.1097/00002030-200203080-00007. AIDS. 2002. PMID: 11872999 Clinical Trial.

5

Savès M, Raffi F, Capeau J, Rozenbaum W, Ragnaud JM, Perronne C, Basdevant A, Leport C, Chêne G; Antiprotéases Cohorte (APROCO) Study Group. Savès M, et al. Among authors: raffi f. Clin Infect Dis. 2002 May 15;34(10):1396-405. doi: 10.1086/339866. Epub 2002 Apr 22. Clin Infect Dis. 2002. PMID: 11981737

6

Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach.

Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti JP; APROCO cohort study group. Spire B, et al. Among authors: raffi f. Soc Sci Med. 2002 May;54(10):1481-96. doi: 10.1016/s0277-9536(01)00125-3. Soc Sci Med. 2002. PMID: 12061483

7

Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial.

Flandre P, Peytavin G, Meiffredy V, Saidi Y, Descamps D, Delagnes M, Brun-Vézinet F, Raffi F; Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team. Flandre P, et al. Among authors: raffi f. Antivir Ther. 2002 Jun;7(2):113-21. Antivir Ther. 2002. PMID: 12212923 Clinical Trial.

8

Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens: the APROVIR Study.

Masquelier B, Peytavin G, Leport C, Droz C, Duran S, Verdon R, Besnier JM, Chêne G, Raffi F, Brun-Vézinet F; APROCO Study Group. Masquelier B, et al. Among authors: raffi f. J Infect Dis. 2002 Nov 15;186(10):1503-7. doi: 10.1086/344358. Epub 2002 Oct 23. J Infect Dis. 2002. PMID: 12404170

9

The detection of non-adherence by self-administered questionnaires can be optimized by protease inhibitor plasma concentration determination.

Duran S, Peytavin G, Carrieri P, Raffi F, Ecobichon JL, Pereira E, Cassuto GP, Spire B, Leport C; Antiprotease Cohort (APROCO) study group. Duran S, et al. Among authors: raffi f. AIDS. 2003 May 2;17(7):1096-9. doi: 10.1097/00002030-200305020-00025. AIDS. 2003. PMID: 12700466

10

R57K polymorphism in the human immunodeficiency virus type 1 protease as predictor of early virological failure in a cohort of antiretroviral-naive patients treated mostly with a nelfinavir-containing regimen.

Masquelier B, Droz C, Dary M, Perronne C, Ferré V, Spire B, Descamps D, Raffi F, Brun-Vézinet F, Chêne G; APROCO/COPILOTE Study Group. Masquelier B, et al. Among authors: raffi f. Antimicrob Agents Chemother. 2003 Nov;47(11):3623-6. doi: 10.1128/AAC.47.11.3623-3626.2003. Antimicrob Agents Chemother. 2003. PMID: 14576131 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

715 results

Search Page